Wockhardt gets green light for three products

MUMBAI, India — Wockhardt has launched three new drugs in the United States over the last three weeks, the Indian generic drug maker said.

Wockhardt announced the Food and Drug Administration's approval and the launch of the company's antibacterial drug levofloxacin, a generic version of Johnson & Johnson’s Levaquin, in the 250-mg, 500-mg and 750-mg strengths.

On May 31, the company launched donepezil tablets, a generic version of Eisai’s Alzheimer’s disease drug Aricept. On June 1, it launched venlafaxine extended-release capsules, a generic version of Pfizer’s antidepressant Effexor XR.

Branded versions of the three drugs have combined sales of $6 billion, according to IMS Health.